J&J partner says EU rejecting drug for MRSA, other skin infections over problems with testing
J&J partner says EU rejecting skin infection drug Novartis seeks to calm fears over swine flu vaccine delivery to USmore images Novartis to pay up to $485M for rights to US firm’s antibiotic for drug-resistant bacteriaNovartis buys rights to next-generation antibiotic BASEL, Switzerland — Novartis AG said Thursday it has bought worldwide rights to a new antibiotic drug developed by U.S. company Paratek Pharmaceuticals to treat drug-resistant bacteria such as MRSA. |